http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4546103-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_133aa645a64f5fe22d35d28af5000c2d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate | 1984-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1985-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1fb7ceaa85eeba622ddc9178432edb6 |
| publicationDate | 1985-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-4546103-A |
| titleOfInvention | Method of treating weight loss disorders |
| abstract | There is disclosed a method of treating weight loss disorders. This method consists essentially of administering to a mammal, such as a human, a daily dosage of at least about 10 milligrams per 37 kilogram body weight of at least one opiate antagonist. These opiate antagonists include naloxone, naltrexone, nalorphine, diprenorphine, levallorphan, pentazocine, metazocine, cyclozocine, etazocine, and pharmacologically acceptable salts thereof. The use of naloxone hydrochloride as the opiate antagonist is preferred. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5426112-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1681057-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4888346-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8067430-B1 |
| priorityDate | 1984-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.